Five Exciting CME Events from Chicago


June 2 – June 5, 2017, Chicago, IL

Five Exciting CME Events from Chicago

Please note that slides are for review only and not to be repurposed or published.

PART 1 — NON-SMALL CELL LUNG CANCER: POINT-COUNTERPOINT

MODULE 1:
Optimizing the Application of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) — Dr Langer

MODULE 2:
Optimal Use of Chemotherapy with or without Biologic Therapy for Metastatic Nonsquamous and Squamous Lung Cancer — Dr Govindan

MODULE 3:
Treatment of NSCLC with Actionable Tumor Mutations — Dr Riely

MODULE 4:
Protocol and Nonresearch Decision-Making for Patients with Localized and Locally Advanced NSCLC — Dr Horn

MODULE 5:
Ongoing Investigation and Future Directions in the Treatment of NSCLC — Prof Soria

PART 2 — GASTROINTESTINAL CANCERS: CASES FROM THE COMMUNITY

MODULE 1:
Biomarker Assessment and Selection of Therapy for Patients with Newly Diagnosed Metastatic Colorectal Cancer (mCRC) — Dr Grothey

MODULE 2:
Clinical and Palliative Care Considerations for Patients with Progressive mCRC — Prof Van Cutsem

MODULE 3:
Existing, Recently Approved and Investigational Approaches for Patients with Pancreatic Adenocarcinoma (PAD) — Dr Chiorean

MODULE 4:
Novel Agents and Strategies in the Management of Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry

MODULE 5:
Protocol and Nonresearch Treatment Decision-Making for Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Dr Fuchs

MODULE 6:
Potential Role of Immune Checkpoint Inhibitors in Patients with mCRC — Dr Overman

PART 3 — OVARIAN CANCER: BREAKFAST WITH THE INVESTIGATORS


Slide presentation

PART 4 — LYMPHOMA AND MULTIPLE MYELOMA: AN EVENING WITH THE INVESTIGATORS


Slide presentation

PART 5 — BREAST CANCER: BEYOND THE GUIDELINES

MODULE 1:
Adjuvant and Neoadjuvant Therapy for HER2-Positive Breast Cancer (BC) — Dr Winer

MODULE 2:
Use of Genomic Assays and Biomarkers to Assist in the Management of ER-Positive EBC — Dr Gral

MODULE 3:
Selection and Sequence of Therapy for Patients with ER-Positive, HER2-Negative Metastatic BC (mBC) — Dr Blackwell

MODULE 4:
Long-Term Management of HER2-Positive mBC — Dr Pegram

MODULE 5:
Potential Role of PARP Inhibition in the Management of BC — Dr Nanda

MODULE 6:
Novel Agents and Strategies Under Active Investigation in BC — Dr Rugo

Investigator Survey:
Slide presentation